Alnylam Pharmaceuticals
ALNY
401 hedge funds and large institutions have $19B invested in Alnylam Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 140 increasing their positions, 132 reducing their positions, and 44 closing their positions.
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
25% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 44
23% more capital invested
Capital invested by funds: $15.4B → $19B (+$3.6B)
3% more funds holding
Funds holding: 391 → 401 (+10)
2.01% more ownership
Funds ownership: 93.53% → 95.54% (+2%)
7% more call options, than puts
Call options by funds: $274M | Put options by funds: $258M
6% more repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 132
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$160M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
+$146M |
| 3 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$139M |
| 4 |
Holocene Advisors
New York
|
+$81.3M |
| 5 |
JP Morgan Chase
New York
|
+$60.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
-$73.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$46.9M |
| 3 |
BlackRock
New York
|
-$46.3M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$34.1M |
| 5 |
APG Asset Management
Amsterdam,
Netherlands
|
-$32.8M |
ALNY Hedge Fund Activity: Q2 2021 in Review
401 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2021, worth a combined $19B — up 23% from $15.4B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new ALNY positions and 44 closed out — a net gain of 11 holders — while 140 added to existing stakes and 132 trimmed.
The largest buyer was Dodge & Cox, adding an estimated $160M. The largest seller was Maverick Capital, cutting an estimated $73.8M.
- 401 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2021, up from 391 in Q1 2021.
- Funds reported $19B of Alnylam Pharmaceuticals stock for Q2 2021, up 23% quarter-over-quarter.
- 55 funds opened new Alnylam Pharmaceuticals positions in Q2 2021 and 44 closed out, a net change of +11 holders.
- The largest Alnylam Pharmaceuticals buyer in Q2 2021 was Dodge & Cox, an estimated $160M added.
- The largest Alnylam Pharmaceuticals seller in Q2 2021 was Maverick Capital, an estimated $73.8M sold.
Based on aggregated 13F filings for Q2 2021.